CLINICAL_TRIALS
trial_result
· 2026-06-25
Clinical Trial Results: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine [Phase 3]
Summary
A Phase 3 study evaluating Lasmiditan (LY573144) for 12 months in children aged 6 to 17 with migraine; study terminated with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Eli Lilly and Company | Conditions: Migraine | Phase 3 | Status: TERMINATED | Results posted: 2026-06-25